Helmut Hettche
26Patents
14h-index
26Co-inventors
77Inventor score
Filing activity: May 1, 1985 → Jul 28, 2000
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4812481A | Synergistic combination of amantadiene and selegiline | Human Necessities | 61 | Expired |
| US5271946A | Controlled release azelastine-containing pharmaceutical compositions | Human Necessities | 61 | Expired |
| US5164194A | Azelastine containing medicaments | Human Necessities | 38 | Expired |
| US5728735A | Pharmaceutical composition containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid as active ingredient | Human Necessities | 37 | Expired |
| US6667058B1 | Oral forms of administration containing solid flupirtine with controlled release of active substance | Human Necessities | 29 | Expired |
| US4778799A | Synergistic combination of flupirtin and non-steroidal antiphlogistic | Human Necessities | 26 | Expired |
| US5086050A | Method of treating inflammatory disorders and psoriasis with salts of azelastine | Human Necessities | 24 | Expired |
| US5084481A | Method of treating inflammatory diseases with pharmaceutical composition containing dihydrolipoic acid as active substance | Human Necessities | 24 | Expired |
| US5693664A | Use of R-(+)-.alpha.-lipoic acid, R-(-)dihydrolipoic acid and metabolites in the form of the free acid or salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae | Human Necessities | 24 | Expired |
| US4668684A | Combination of flupirtin and anticholinergic acting spasmolytic | Human Necessities | 24 | Expired |
| US6017909A | Salts of azelastine having improved solubility effective at treating psoriasis and providing a cytoprotective effect | Human Necessities | 17 | Expired |
| US6271254A | Pharmaceutical compositions containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid as active ingredient | Human Necessities | 16 | Expired |
| US5376382A | Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms of thioctic acid | Human Necessities | 15 | Expired |
| US5415853A | Compressed gas packages using polyoxyethylene glyceryl oleates | Human Necessities | 15 | Expired |
| US5536444A | Compressed-gas packages using polyoxyethylene glyceryl fatty-acid esters as suspension stabilizers and valve lubricants | Human Necessities | 13 | Expired |
| US5068233A | Synergistic combination of azelastine and theophylline or azelastine and .alpha.-mimetics | Human Necessities | 12 | Expired |
| US5503845A | Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms | Human Necessities | 12 | Expired |
| US6117899A | Use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as its sequelae | Human Necessities | 9 | Expired |
| US5859003A | Salts of azelastine having improved solubility | Human Necessities | 8 | Expired |
| US5948810A | Use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae | Human Necessities | 8 | Expired |
| US5527539A | Tablets with thioctic acid of specific particle size | Human Necessities | 7 | Expired |
| US5990152A | Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability | Human Necessities | 7 | Expired |
| US4673666A | 2-amino-3-ethoxycarbonylamino-6-(p-fluoro-benzylamino)-pyridine gluconate and pharmaceutical preparations containing it | Chemistry; Metallurgy | 7 | Expired |
| US5998403A | Salts of azelastine having improved solubility useful at providing a cytoprotective effect | Human Necessities | 5 | Expired |
| US6348490B1 | Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability | Human Necessities | 5 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.